Perrigo opposes FDA proposed phenolphthalein ban due to lack of human data.
This article was originally published in The Tan Sheet
Executive Summary
FDA PHENOLPHTHALEIN BAN NOT SUPPORTED BY EXISTING DATA, PERRIGO maintains in comments on the agency's recent proposal to reclassify the OTC stimulant laxative ingredient from Category I (generally recognized as safe and effective) to Category II (not generally recognized as safe and effective) and to list phenolphthalein as a nonmonograph ingredient. The agency's Sept. 2 proposal is based on National Toxicology Program data suggesting phenolphthalein's carcinogenic potential in rodents ("The Tan Sheet" Sept. 1, p. 1).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning